Dr. Charles Lin attended the first Warriors Against Chordoma Hoops Challenge in Austin, Texas this spring. The event supported research being done with the Chordoma Foundation and was a huge success! Dr. Lin remarks on the progress being made in Chordoma research during the event and highlights what’s to come. Find out more about the Chordoma Foundation here .
2nd Annual THINC Symposium welcomed distinguished leaders in drugging gene control from both academia and industry!
Leaders of studying and drugging gene control in both academia and industry were brought together to highlight research and further understanding in diseases of gene regulation. The 2nd Annual THINC Symposium was hosted April 11-12, 2019 at Baylor College of Medicine. Full agenda can be found here.
thinc group leader publishes in cell chemical biology!
Calla Olson, Ph.D. published a paper on the development of a selective CDK7 inhibitor. The full article in Cell Chemical Biology can be found here.
A multidisciplinary international team of scientists; including Dr. Trey Westbrook as been awarded in the CRUK Grand Challenges. Team SPECIFICANCER will focus on understanding why cancers grow in some tissues and not in others.
1st Annual THINC Symposium - Great Success!
Distinguished leaders of studying and drugging gene control in both academia and industry were brought together to further our understanding of diseases of gene regulation, especially RNA and chromatin biology, at the 1st Annual THINC Symposium held May 31, 2018 - June 1, 2018. These excellent speakers brought diverse expertise, which was met with great enthusiasm by trainees, researchers, and anyone interested in gene regulation and therapeutics. Q&A sessions after each talk were engaging, providing an excellent opportunity for participants to interact with prominent speakers on the themes of RNA & Disease, Academic Drug Discovery, and Drugging Transcription!
Top Row: Charles Lin, Ph.D. (Baylor College of Medicine/THINC), Richard A. Young, Ph.D. (Whitehead Institute, MIT), Casey Cunningham, M.D. (Santé Ventures), Damian Young, Ph.D. (Baylor College of Medicine/THINC), Paul Clarke, Ph.D. (ICR London), and Michael Foley, Ph.D. (Tri-Institutional Therapeutics Discovery Institute).
Middle Row: Silvia Buonamici, Ph.D. (H3 Biomedicine), Noreen Rizvi, Ph.D. (Merck & Co; Siemens Healthineers), Rajesh Chopra, Ph.D. (ICR London), and Trey Westbrook, Ph.D. (Baylor College of Medicine/THINC).
Bottom Row: Arthur T. Sands, M.D., Ph.D. (Nurix), Huda Zoghbi, M.D. (Baylor College of Medicine), H. Courtney Hodges, Ph.D. (Baylor College of Medicine), Eric Wang, Ph.D. (University of Florida), and Louis Chesler, M.D., Ph.D. (ICR London)
A team of researchers and physician-scientists, led by Baylor College of Medicine identifies a novel treatment strategy that may be effective for TNBC patients.